A biotech CEO who sold his last company for $14 billion explains why he wants to do things differently this time

Axovant Sciences David Hung wants to do things differently at his new company. Hung's the CEO of Axovant, a company that has a shot tolaunch the first new Alzheimer's drug in 15 years. Before joining the company in April, Hung founded Medivation, a cancer drugmaker based San Francisco that Pfizer bought for $14 billion inAugust 2016. But selling Medivation wasn't initially part of the plan. And now he'strying to make sure it doesn't happen again. "We never looked to get acquired," Hung said. "We...